Where does Denali Therapeutics Inc.'s cash flow data come from?

Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$508.02M-11.9%	-$512.54M-21.2%	-$498.74M-16.7%	-$479.03M-14.1%	-$453.94M-231%
Depreciation and amortization	$11.7M+47.1%	$11.18M+43.5%	$10.17M+25.3%	$9.06M+6.6%	$7.96M-10.0%
Stock-based compensation	$97.56M-2.6%	$99.63M-3.2%	$100.76M-2.9%	$100.49M-5.5%	$100.2M-7.1%
Net cash from operating activities	-$412.34M-12.8%	-$412.6M-18.7%	-$397.78M-9.7%	-$349.62M+10.6%	-$365.54M+11.5%
Capital expenditures	——	——	——	$18.33M+63.1%	$18.84M+53.1%
Net cash from investing activities	$330.99M—	$255.28M—	——	——	——
Net cash from financing activities	$412.02M—	$189.22M—	——	——	——
Net increase (decrease) in cash	$330.68M—	$31.9M—	$1.86M—	——	——
Free cash flow	-$419.23M-9.1%	-$422.1M-16.1%	-$410.85M-9.4%	-$367.95M+8.5%	-$384.38M+9.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Denali Therapeutics Inc.'s cash flow data come from?: Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.